JPMorgan Starts ConforMIS (CFMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
UPDATE: Oppenheimer Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:40 AM EDT(Updated - July 27, 2015 9:12 AM EDT)
Oppenheimer initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating and a price target of $26.
Analyst Steven Lichtman said, "CFMS's unique iFit technology provides custom implants designed to match the individual anatomy of a patient undergoing total... More
Wells Fargo Starts ConforMIS (CFMS) at Outperform
July 27, 2015 7:38 AM EDTWells Fargo initiated coverage on ConforMIS (NASDAQ: CFMS) with an Outperform rating.
For an analyst ratings summary and ratings history on ConforMIS click here. For more ratings news on ConforMIS click here.
Shares of ConforMIS closed at $22.12 yesterday.
... MoreUPDATE: Canaccord Genuity Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:37 AM EDT(Updated - July 27, 2015 8:47 AM EDT)
Canaccord Genuity initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.00.
Analyst William J. Plovanic said, "We believe ConforMIS is a disruptive technology in the multi-billion dollar global orthopedic implant market.... More
Deutsche Bank Starts ConforMIS (CFMS) at Buy
July 27, 2015 7:36 AM EDTDeutsche Bank initiated coverage on ConforMIS (NASDAQ: CFMS) with a Buy rating and a price target of $27.
Analyst Kristen Stewart said, "ConforMIS is an orthopedic manufacturer of fully customized implants utilizing its iFit technology--iFit design, iFit printing (3D printing), and iFit just-in-time... More
